Prosensa and GlaxoSmithKline initiate development of four additional products under alliance in Duchenne Muscular Dystrophy

25-Jun-2010 - Netherlands

Prosensa announced the initiation of two further programmes under its existing alliance with GSK covering novel RNA-based treatments for Duchenne muscular dystrophy (DMD). The initiation of these additional programs under the terms of the existing alliance agreement is a validation of both the potential of Prosensa’s “exon skipping” platform and the ongoing relationship.

The two new programs are included under the existing alliance agreement between both parties and will address the development of four compounds which target different subpopulations of patients suffering from DMD. To access these new programs, GSK has made two initiation payments to Prosensa and Prosensa becomes eligible for further pre-option milestone payments based on research progress.

Within these new programs, Prosensa and GSK will focus on the skipping of four exons (i.e. exon 45, 52, 53, and 55), in addition to their existing programs which target skipping of exon 51 and 44 (PRO051/GSK2402968 and PRO044). The initiation of these programs confirms the joint commitment of both companies to find treatments for DMD.

Under the terms of the collaboration, GSK has an option to select two of these additional four compounds for later-stage development and commercialization. Prosensa will retain certain limited European commercialization rights alongside GSK for the two compounds selected by GSK. For the two compounds not selected by GSK, Prosensa will retain full commercialization rights.

https://www.bionity.com/en/news/119357/prosensa-and-glaxosmithkline-initiate-development-of-four-additional-products-under-alliance-in-duchenne-muscular-dystrophy.html